Draconis Pharma Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Out of Business

Draconis Pharma General Information

Description

Developer of an immunological response drug intended to focus on research and new therapies. The company specializes in customized services to evaluate, the efficacy, safety, and toxicology of many types of compounds, such as small molecules, proteins, antibodies, RNA-based compounds, vaccines, functional foods, or probiotics, in a wide range of targets and disease experimental models, providing pharmaceutical, biotechnological and food companies with experimental services in the early stages of discovery and pre-clinical research.

Contact Information

Website
www.draconispharma.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Cl Pallars 179
  • 08005 Barcelona
  • Spain
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Cl Pallars 179
  • 08005 Barcelona
  • Spain

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Draconis Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 12-Aug-2024 Completed Out of Business
1. Later Stage VC 18-Feb-2021 Completed Pre-Clinical Trials
To view Draconis Pharma’s complete valuation and funding history, request access »

Draconis Pharma Patents

  • 10

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • Pending

  • Expiring in next 12 mo

Draconis Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150376129-A1 Substituted benzamides with activity towards ep4 receptors Active 27-Feb-2013
US-9926276-B2 Substituted benzamides with activity towards ep4 receptors Active 27-Feb-2013
CA-2900599-A1 Substituted benzamides with activity towards ep4 receptors Active 07-Feb-2013
ES-2615742-T3 Benzamides substituted with activity towards ep4 receptors Active 07-Feb-2013
CA-2900599-C Substituted benzamides with activity towards ep4 receptors Active 07-Feb-2013 C07D213/81
To view Draconis Pharma’s complete patent history, request access »

Draconis Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Draconis Pharma FAQs

  • When was Draconis Pharma founded?

    Draconis Pharma was founded in 2010.

  • Where is Draconis Pharma headquartered?

    Draconis Pharma is headquartered in Barcelona, Spain.

  • What is the size of Draconis Pharma?

    Draconis Pharma has 6 total employees.

  • What industry is Draconis Pharma in?

    Draconis Pharma’s primary industry is Drug Discovery.

  • Is Draconis Pharma a private or public company?

    Draconis Pharma is a Private company.

  • What is Draconis Pharma’s current revenue?

    The current revenue for Draconis Pharma is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »